MX2013001240A - Inhibidores de metaloproteinas de matriz. - Google Patents
Inhibidores de metaloproteinas de matriz.Info
- Publication number
- MX2013001240A MX2013001240A MX2013001240A MX2013001240A MX2013001240A MX 2013001240 A MX2013001240 A MX 2013001240A MX 2013001240 A MX2013001240 A MX 2013001240A MX 2013001240 A MX2013001240 A MX 2013001240A MX 2013001240 A MX2013001240 A MX 2013001240A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- matrix metalloproteinase
- relates
- present
- over
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1810DE2010 | 2010-07-30 | ||
PCT/IB2011/053155 WO2012014114A1 (en) | 2010-07-30 | 2011-07-14 | Matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013001240A true MX2013001240A (es) | 2013-08-27 |
Family
ID=44720049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013001240A MX2013001240A (es) | 2010-07-30 | 2011-07-14 | Inhibidores de metaloproteinas de matriz. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2598493A1 (pt) |
JP (1) | JP2013537533A (pt) |
KR (1) | KR20130042590A (pt) |
CN (1) | CN103119030A (pt) |
AU (1) | AU2011284397A1 (pt) |
BR (1) | BR112013002370A2 (pt) |
CA (1) | CA2807097A1 (pt) |
CO (1) | CO6680674A2 (pt) |
MX (1) | MX2013001240A (pt) |
SG (1) | SG187654A1 (pt) |
WO (1) | WO2012014114A1 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
CA2871778C (en) | 2012-05-03 | 2022-09-13 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
KR102154880B1 (ko) | 2012-05-03 | 2020-09-10 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
CN103254290B (zh) * | 2013-05-30 | 2014-09-03 | 南通广泰生化制品有限公司 | 基质金属蛋白酶-2多肽抑制剂及其应用 |
CN103304634B (zh) * | 2013-05-30 | 2015-04-29 | 温州芳植生物科技有限公司 | 基质金属蛋白酶-2多肽抑制剂及其应用 |
AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN106661008A (zh) | 2014-04-03 | 2017-05-10 | 拜耳制药股份公司 | 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸 |
WO2015150364A1 (de) * | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Substituierte benzotriazinonbutansäuren und ihre verwendung |
CN106458938A (zh) | 2014-04-03 | 2017-02-22 | 拜耳制药股份公司 | 手性2,5‑二取代的环戊烷甲酸衍生物及其用途 |
WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
WO2015150366A1 (de) * | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Cyclisch substituierte phenolether-derivate und ihre verwendung |
WO2015189117A1 (de) * | 2014-06-12 | 2015-12-17 | Bayer Pharma Aktiengesellschaft | Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
US3937838A (en) | 1966-10-19 | 1976-02-10 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds and their preparation |
US3700681A (en) | 1971-02-16 | 1972-10-24 | Pfizer | 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines |
US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
US4011258A (en) | 1973-06-21 | 1977-03-08 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds |
DE3163871D1 (en) | 1980-07-09 | 1984-07-05 | Draco Ab | 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
CA1240708A (en) | 1983-11-15 | 1988-08-16 | Johannes K. Minderhoud | Process for the preparation of hydrocarbons |
GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
AU2001245862A1 (en) | 2000-03-21 | 2001-10-03 | The Procter & Gamble Company | Difluorobutyric acid metalloprotease inhibitors |
MXPA03006876A (es) | 2001-01-30 | 2003-11-13 | Pfizer Prod Inc | Intermedios y procedimientos para preparar derivados de cromanol sustituido. |
US6794510B2 (en) | 2002-08-08 | 2004-09-21 | Adolor Corporation | Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto |
GB0312654D0 (en) | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
CA2598518C (en) | 2005-02-22 | 2015-04-21 | Ranbaxy Laboratories Limited | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases |
JP5399902B2 (ja) | 2006-08-22 | 2014-01-29 | ランバクシー ラボラトリーズ リミテッド | マトリックスメタロプロテイナーゼ阻害剤 |
-
2011
- 2011-07-14 EP EP11763767.8A patent/EP2598493A1/en not_active Withdrawn
- 2011-07-14 BR BR112013002370A patent/BR112013002370A2/pt not_active IP Right Cessation
- 2011-07-14 KR KR1020137005055A patent/KR20130042590A/ko not_active Application Discontinuation
- 2011-07-14 CA CA2807097A patent/CA2807097A1/en not_active Abandoned
- 2011-07-14 SG SG2013007448A patent/SG187654A1/en unknown
- 2011-07-14 WO PCT/IB2011/053155 patent/WO2012014114A1/en active Application Filing
- 2011-07-14 MX MX2013001240A patent/MX2013001240A/es not_active Application Discontinuation
- 2011-07-14 AU AU2011284397A patent/AU2011284397A1/en not_active Abandoned
- 2011-07-14 CN CN2011800461515A patent/CN103119030A/zh active Pending
- 2011-07-14 JP JP2013522322A patent/JP2013537533A/ja not_active Withdrawn
-
2013
- 2013-02-28 CO CO13040146A patent/CO6680674A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2598493A1 (en) | 2013-06-05 |
JP2013537533A (ja) | 2013-10-03 |
CO6680674A2 (es) | 2013-05-31 |
BR112013002370A2 (pt) | 2017-06-20 |
AU2011284397A1 (en) | 2013-02-21 |
CN103119030A (zh) | 2013-05-22 |
WO2012014114A1 (en) | 2012-02-02 |
KR20130042590A (ko) | 2013-04-26 |
CA2807097A1 (en) | 2012-02-02 |
SG187654A1 (en) | 2013-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013001240A (es) | Inhibidores de metaloproteinas de matriz. | |
EA201390404A1 (ru) | Ингибиторы матричной металлопротеиназы | |
PH12012502420A1 (en) | Matrix metalloproteinase inhibitors | |
EA201390405A1 (ru) | Ингибиторы матричной металлопротеиназы | |
JOP20210065A1 (ar) | عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة | |
MX2014007254A (es) | Composiciones farmaceuticas que comprenden glitazonas y activadores de nrf2. | |
UA100983C2 (ru) | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты | |
NZ595819A (en) | DIHYDROOROTATE DEHYDROGENASE INHIBITORS; benzimidazole-4-carboxylic acid | |
TW200801027A (en) | Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids | |
LT2229351T (lt) | Didelio grynumo laipsnio 2-[4-(3- arba 2-fluorbenziloksi)benzilamino]propanamidų gamybos būdas | |
NI200700220A (es) | Derivados de ácido 5-fenil-pentanóico como inhibidores de metaloproteinasa de la matriz para el tratamiento del asma y otras enfermedades | |
HK1169647A1 (en) | Process for the production of ethanol by hydrogenation of vaporized acetic acid | |
EP3789420A4 (en) | SYNTHESIS PROCESS FOR THE SINGLE-STAGE PRODUCTION OF MONOMERIC POLYETHER FOR POLYCARBONIC ACID WATER REDUCTION AGENTS | |
CL2011000093A1 (es) | Compuestos derivados de un ester piperidinilico del acido bifenil-2-ilcarbamico; composicion farmaceutica; combinacion farmaceutica; y su uso para broncoconstriccion, enfermedades obstructivas o inflamatorias de las vias respiratorias. | |
CR20120630A (es) | Nuevos procesos | |
MX2018010334A (es) | Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak). | |
CU23718B7 (es) | Derivados del ácido 5-fenil-pentanoico como inhibidores de la metaloproteinasa de la matriz. | |
NZ603802A (en) | Pyrimidinyl indole compounds | |
TN2014000227A1 (en) | Method for producing substituted 5-fluoro-1h-pyrazolopyridines | |
TH75572B (th) | กรรมวิธีการสังเคราะห์ตัวเร่งปฏิกิริยาจากผลิตผลพลอยได้ (By Product) ของกระบวนการผลิตแอสฟัลติกคอนกรีต (Asphaltic Concrete) และการใช้ตัวเร่งปฏิกิริยาดังกล่าว | |
TN2013000243A1 (en) | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |